Trade

with

Antares Pharma Inc
(NASDAQ: ATRS)
AdChoices
2.01
+0.03
+1.52%
After Hours :
2.01
+0.00
+0.01%

Open

2.01

Previous Close

1.98

Volume (Avg)

592.18k (1.11M)

Day's Range

1.97-2.05

52Wk Range

1.82-5.01

Market Cap.

262.24M

Dividend Rate ( Yield )

-

Beta

0.42

Shares Outstanding

130.47M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Medical Instruments & Supplies
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 20.62M

    • Net Income

    • -20.51M

    • Market Cap.

    • 262.24M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -137.21

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 0.42

    • Forward P/E

    • 49.50

    • Price/Sales

    • 11.70

    • Price/Book Value

    • 4.66

    • Price/Cash flow

    • -13.19

      • EBITDA

      • -20.29M

      • Return on Capital %

      • -34.69

      • Return on Equity %

      • -44.32

      • Return on Assets %

      • -34.69

      • Book Value/Share

      • 0.42

      • Shares Outstanding

      • 130.47M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 4.00

        • Credit Rating

        • -

        • Analysts

        • 1

        • EPS Estimate

        • 0.04

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 8.40

          • 10.42

          • Net Income

            YTD/YTD (last year)

          • -

          • -15.59

          • Net Income

            Q/Q (last year)

          • -

          • -8.93

          • Sales (Revenue)

            5-Year Annual Average

          • 29.50

          • 12.51

          • Net Income

            5-Year Annual Average

          • -

          • 4.16

          • Dividends

            5-Year Annual Average

          • -

          • 0.97

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 67.88

            • 52.83

            • Pre-Tax Margin

            • -138.59

            • 15.96

            • Net Profit Margin

            • -137.21

            • 12.40

            • Average Gross Margin

              5-Year Annual Average

            • 57.80

            • 52.66

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 18.40

            • Average Net Profit Margin

              5-Year Annual Average

            • -69.60

            • 93.46B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.62

              • Current Ratio

              • 3.13

              • 1.97

              • Quick Ratio

              • 2.66

              • 1.16

              • Interest Coverage

              • -

              • 10.47

              • Leverage Ratio

              • 1.49

              • 2.38

              • Book Value/Share

              • 0.42

              • 12.11

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -8.57

                • 35.97

                • P/E Ratio 5-Year High

                • -24.03

                • 279.76

                • P/E Ratio 5-Year Low

                • -4.35

                • 148.87

                • Price/Sales Ratio

                • 11.75

                • 3.33

                • Price/Book Value

                • 4.68

                • 4.16

                • Price/Cash Flow Ratio

                • -13.19

                • 17.27

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -44.32

                    (-55.10)

                  • 17.93

                    (21.42)

                  • Return on Assets %

                    (5-Year Average)

                  • -34.69

                    (-28.50)

                  • 7.35

                    (9.50)

                  • Return on Capital %

                    (5-Year Average)

                  • -44.32

                    (-50.30)

                  • 10.24

                    (13.59)

                  • Income/Employee

                  • -

                  • 25.65k

                  • Inventory Turnover

                  • 1.49

                  • 2.66

                  • Asset Turnover

                  • 0.25

                  • 0.59

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -20.85M
                  Operating Margin
                  -101.12
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -13.19
                  Ownership

                  Institutional Ownership

                  33.84%

                  Top 10 Institutions

                  24.94%

                  Mutual Fund Ownership

                  9.46%

                  Float

                  89.77%

                  5% / Insider Ownership

                  9.68%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Vanguard Total Stock Mkt Idx

                  •  

                    1,912,926

                  • 2.57

                  • 1.47

                  • iShares Russell 2000 (AU)

                  •  

                    1,826,157

                  • -0.90

                  • 1.53

                  • Vanguard Extended Market Index Fund

                  •  

                    1,295,076

                  • 0.44

                  • 0.99

                  • iShares Russell 2000 Growth

                  •  

                    818,905

                  • -0.45

                  • 0.69

                  • Putnam Global Health Care Fund

                  •  

                    650,400

                  • 0.00

                  • 0.50

                  • Fidelity Spartan® Extended Mkt Indx Fd

                  •  

                    441,109

                  • 0.00

                  • 0.34

                  • UBS U.S. Small Capitalization Growth Fun

                  •  

                    400,000

                  • 0.00

                  • 0.31

                  • CREF Stock

                  •  

                    364,671

                  • 0.00

                  • 0.28

                  • iShares Micro-Cap

                  •  

                    293,377

                  • 0.84

                  • 0.25

                  • Vanguard Instl Total Stock Market Index

                  •  

                    258,527

                  • 0.00

                  • 0.20

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Deerfield Management Co

                  •  

                    9,603,703

                  • +1.21%

                  • 7.37

                  • Millennium Management LLC

                  •  

                    4,067,481

                  • +81.05%

                  • 3.12

                  • BlackRock Fund Advisors

                  •  

                    3,995,423

                  • -1.70%

                  • 3.07

                  • Vanguard Group, Inc.

                  •  

                    3,875,750

                  • +2.79%

                  • 2.97

                  • Broadfin Capital, LLC

                  •  

                    3,050,000

                  • +32.61%

                  • 2.34

                  • Harris William Investors Inc

                  •  

                    2,338,735

                  • +54.50%

                  • 1.79

                  • State Street Corp

                  •  

                    2,003,165

                  • -0.01%

                  • 1.54

                  • Northern Trust Investments, N.A.

                  •  

                    1,313,397

                  • -10.53%

                  • 1.01

                  • Kingdon Capital Management LLC

                  •  

                    1,165,738

                  • -21.80%

                  • 0.89

                  • Ashford Capital Management Inc

                  •  

                    1,088,675

                  • +26.51%

                  • 0.84

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Medical Instruments & Supplies

                  Type

                  Distressed

                  Style

                  Small Growth

                  Antares Pharma, Inc., formerly known as Medi-Ject Corporation, or Medi-Ject, was incorporated on February 1979. The Company is a specialty pharmaceutical company developing and commercializing self-administered parenteral pharmaceuti...morecal products and technologies. It has a number of partnerships with pharmaceutical companies as well as internal product development programs. It develops both subcutaneous and intramuscular injection technology systems. It launched OTREXUP injection on January 2014, is a subcutaneous methotrexate for once weekly self-administration with an easy-to-use, single dose, disposable auto injector. It is indicated for adults with severe active rheumatoid arthritis or children with active polyarticular juvenile idiopathic arthritis and adults with severe recalcitrant psoriasis. ...moreThe Company has international marketing rights for its OTREXUP. It is also developing Vibex QS for testosterone replacement therapy for men suffering from symptomatic testosterone deficiency. The Company has licensed its reusable needle-free injection device for use with human growth hormone to Teva Pharmaceutical Industries, Ltd., Ferring Pharmaceuticals BV and JCR Pharmaceuticals Co., Ltd., with Teva and Ferring being two of the Company's primary customers. The Company's needle-free injection device is marketed by Teva as the Tjet injector system to administer their 5mg Tev-Tropin brand hGH marketed in the U.S. The Company's needle-free injection device is marketed by Ferring with their 4mg and 10mg hGH formulations as Zomajet 2 Vision and Zomajet Vision X, respectively, in Europe and Asia. It has also licensed both disposable auto and pen injection devices to Teva for use in certain fields and territories and is engaged in product development activities for Teva utilizing these devices. It also has a portfolio of gel-based products such as Gelnique, a topical oxybutynin gel product for the treatment of overactive bladder. Gelnique is marketed by Actavis in the U.S. In South Korea, Gelnique is marketed by Daewoong Pharmaceuticals. The Company sells its proprietary reusable needle-free injectors and related disposable products to pharmaceutical partners and through medical product distributors. The Company's competitors include Pfizer, NovoNordisk, Warner-Chilcott, Novartis, Mylan, Roxane, Bedford Labs, Hospira, among others.lessless

                  Key People

                  Eamonn P. Hobbs

                  Director/President/CEO

                  Dr. Leonard S. Jacob,M.D.,PhD

                  Chairman of the Board/Director

                  Robert F. Apple

                  COO/CFO/Chief Accounting Officer/Executive VP

                  Jack Howarth

                  Vice President, Divisional

                  Anton G. Gueth

                  Director

                  • Antares Pharma Inc

                  • 100 Princeton South

                  • Ewing, NJ 08628

                  • USA.Map

                  • Phone: +1 609 359-3020

                  • Fax: -

                  • antarespharma.com

                  Incorporated

                  1979

                  Employees

                  60

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: